Cumberland Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPIX) $1.77 +0.10 (+5.99%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.65▼$1.7750-Day Range$1.60▼$2.3052-Week Range$1.43▼$2.91Volume4,824 shsAverage Volume20,459 shsMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX)Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More CPIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPIX Stock News HeadlinesNovember 28, 2023 | msn.comMan dies after Cumberland County shooting late MondayNovember 27, 2023 | msn.comGroup to meet to set demolition date for old U.S. 60 Cumberland River ‘Smithland’ BridgeNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 27, 2023 | news.yahoo.comCumberland man arrested in handgun assaultNovember 27, 2023 | msn.comMost recent median home sales in Cumberland County down slightlyNovember 27, 2023 | nj.comSee all homes sold in Cumberland County, Nov. 20 to Nov. 26November 26, 2023 | msn.comCumberland Council unveils new gum-busting machinesNovember 24, 2023 | msn.comMultiple injuries reported following rollover crash on I-81 in Cumberland CountyNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 24, 2023 | msn.comSuspect arrested after hours-long standoff in Cumberland CountyNovember 24, 2023 | msn.comMan arrested for assault after Cumberland Co. police respond for six hoursNovember 24, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)November 23, 2023 | msn.comCumberland Council: Austerity blamed for overspendNovember 23, 2023 | msn.comNumber of electric car charging points rose by a fifth in CumberlandNovember 23, 2023 | yahoo.comCumberland: 'State-of-the-art' gum-removal machine unveiledNovember 23, 2023 | msn.comCumberland councillors approve own 20% payriseNovember 23, 2023 | sports.yahoo.comCumberland's Kibiwott takes 46th at NAIA nationalsNovember 22, 2023 | msn.comBobcat spotted in CumberlandNovember 22, 2023 | msn.comCumberland County English teacher handcuffed outside class at end of school fundraiserNovember 22, 2023 | msn.comCumberland hosts signing day celebration for 7 student-athletesNovember 22, 2023 | msn.comCumberland County OKs proposal to build new parking deck in downtown FayettevilleNovember 22, 2023 | msn.comPolice: Suspect steals Cumberland County resident's identity to make more than $8,000 in fraudulent cash withdrawalsNovember 21, 2023 | msn.com24 is more than just a number for Cumberland High School footballNovember 21, 2023 | msn.comCumberland County man gets 20-year minimum prison term for causing baby’s deathNovember 21, 2023 | msn.comMarvin Connelly of Cumberland County Schools named top superintendent in North CarolinaNovember 21, 2023 | msn.comCumberland restaurant handed new five-star food hygiene ratingNovember 21, 2023 | news.yahoo.comCumberland County prepares for white flag shelter nights, but some say there aren't enoughSee More Headlines Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CPIX CUSIP23077010 CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees85Year Founded1999Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,570,000.00 Net Margins-6.17% Pretax Margin-6.15% Return on Equity8.68% Return on Assets3.49% Debt Debt-to-Equity Ratio0.36 Current Ratio1.53 Quick Ratio1.21 Sales & Book Value Annual Sales$42.01 million Price / Sales0.58 Cash Flow$0.47 per share Price / Cash Flow3.65 Book Value$2.45 per share Price / Book0.70Miscellaneous Outstanding Shares14,260,000Free Float8,259,000Market Cap$24.38 million OptionableOptionable Beta0.22 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. A. J. Kazimi MBA (Age 65)Founder, Chairman, President & CEO Comp: $897.5kMr. John Michael Hamm (Age 67)Chief Financial Officer Comp: $231.38kMr. James Lowrance Herman (Age 68)Executive VP of National Accounts & Chief Compliance Officer Comp: $352.65kMs. Jean W. Marstiller (Age 73)Senior VP of Administrative Services & Corporate Secretary Comp: $282.17kMr. Chris T. Bitterman (Age 58)Vice President of Sales & Marketing Mr. Adam S. Mostafa (Age 43)Managing Director Mr. Todd M. Anthony (Age 62)Vice President of Organizational Development Ms. Erin Smith GullSenior Corporate Relations AssociateMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRLumos PharmaNASDAQ:LUMONRx PharmaceuticalsNASDAQ:NRXPMarker TherapeuticsNASDAQ:MRKRSio Gene TherapiesNASDAQ:SIOXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 75,268 shares on 10/24/2023Ownership: 0.524%James JonesBought 88 shares on 12/21/2022Total: $195.36 ($2.22/share)Caroline YoungBought 30 shares on 12/19/2022Total: $66.30 ($2.21/share)Caroline YoungBought 20 shares on 12/16/2022Total: $44.40 ($2.22/share)Caroline YoungBought 20 shares on 12/14/2022Total: $44.20 ($2.21/share)View All Insider TransactionsView All Institutional Transactions CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed in 2023? Cumberland Pharmaceuticals' stock was trading at $2.25 at the beginning of the year. Since then, CPIX stock has decreased by 21.3% and is now trading at $1.77. View the best growth stocks for 2023 here. Are investors shorting Cumberland Pharmaceuticals? Cumberland Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 18,600 shares, a drop of 25.6% from the October 31st total of 25,000 shares. Based on an average daily trading volume, of 18,100 shares, the short-interest ratio is presently 1.0 days. Currently, 0.2% of the company's stock are short sold. View Cumberland Pharmaceuticals' Short Interest. When is Cumberland Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our CPIX earnings forecast. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday, November, 7th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $10.09 million for the quarter. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 8.68% and a negative net margin of 6.17%. What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO? 9 employees have rated Cumberland Pharmaceuticals Chief Executive Officer A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among the company's employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), Xeris Biopharma (XERS). Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.52%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include A J Kazimi, A J Kazimi, Caroline Young, James Jones, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas. View institutional ownership trends. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CPIX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.